Tag: Medicines New Zealand

Trans-Pacific Partnership: A Mixed Bag for NZ Patients

Press Release – Medicines New Zealand Medicines New Zealand believes that strong intellectual property protections are necessary for the discovery and development of new treatments and therapies for New Zealand patients, including innovative biologic medicines. The limitation placed … Trans-Pacific Partnership: A Mixed Bag for New Zealand Patients Medicines New Zealand believes that strong intellectual property protections are necessary for the discovery and development of new treatments and therapies for New Zealand patients, including innovative biologic medicines. “The limitation placed on the term of data protection for biologics is disappointing as in some cases this is the only form of intellectual property protection available for innovative medicines” said Dr Graeme Jarvis, General Manager of Medicines New Zealand. “However, we are pleased that as a result of TPP, PHARMAC will have to be more transparent and timely on its decision-making processes. This, we hope, may lead to patients getting more appropriate access to innovative medicines, as the current list still has products that have been waiting 8 years for final approval and funding.” Medicines New Zealand is currently reviewing the recently released text of the Agreement to determine the full extent and impact of the provisions affecting the innovative medicines industry in New Zealand. “It is however clear that the big issue raised by critics regarding the demise of PHARMAC has been significantly exaggerated” “The industry looks forward to engaging...

Read More

Medicines New Zealand Statement on the TPP

Press Release – Medicines New Zealand Medicines New Zealand Statement on the Trans-Pacific Partnership Negotiations 6 October 2015 Medicines New Zealand believes signing of the TPP has potential to boost the New Zealand economy by between $2-4 billion per year, open up new markets for …Medicines New Zealand Statement on the Trans-Pacific Partnership Negotiations 6 October 2015 Medicines New Zealand believes signing of the TPP has potential to boost the New Zealand economy by between $2-4 billion per year, open up new markets for our exporters, and allow New Zealanders improved access to innovative and beneficial goods including medicines and vaccines. There appears to be no change in the cost of subsidised medicines to patients as a result of TPP, which is a good outcome for New Zealanders. It is disappointing that better IP protection for novel biologic medicines through data exclusivity has not been agreed to, but it is positive that at least a baseline protection will now exist across the TPP countries. “While we are yet to see the full details of the agreement, we are pleased that some aspects of timeliness and transparency in the PHARMAC process appear to have been addressed, without any change to the PHARMAC structure” said Hon Heather Roy, Chair of Medicines New Zealand. “We have consistently asked for definitive timelines for decision-making on medicines and vaccine funding applications and an appeals...

Read More

Capturing Value from Innovation Vital for NZ

Press Release – Medicines New Zealand New Zealand’s innovative companies and research community must protect their breakthroughs, for the country to continue to grow its science based economy, a group of visiting IP and investment experts say. Joseph Damond, Senior Vice President (International), …Capturing Value from Innovation Vital for NZ New Zealand’s innovative companies and research community must protect their breakthroughs, for the country to continue to grow its science based economy, a group of visiting IP and investment experts say. Joseph Damond, Senior Vice President (International), Biotechnology Industry Association (BIO), Washington, Richard Kjeldgaard Deputy Vice President (Intellectual Property), Pharmaceutical Research and Manufacturers of America (PhRMA), Washington, and Joshua Funder, Partner, GBS Venues, Australia, have been talking to local high tech firms developing pharmaceutical and biotechnology products, discussing best practice policies for IP protection. “Opportunities for cross border collaboration in medical research have never been stronger,” Mr Damond says. “For smaller companies, start-ups and research institutes to attract funding and capture value from their innovative products and ideas, adequate intellectual property protection is vital,” Mr Damond adds. “The current Trans Pacific Partnership negotiations are an opportunity to enhance and align IP protection across the Asia-Pacific countries involved,” Medicines New Zealand General Manager Kevin Sheehy says. “These standards provide the certainty companies need to warrant investing in early stage New Zealand-based innovations. Unifying those standards across the Asia Pacific region...

Read More

Improved Access to Innovative Medicines Good for NZ Patients

Press Release – Medicines New Zealand Providing solutions to help New Zealand’s health system better serve its people is at the heart of Medicines New Zealand’s message at the Trans Pacific Partnership meetings in Dallas this week. In a speech delivered to a stakeholder meeting in Dallas, …Improved Access to Innovative Medicines Good for NZ Patients Providing solutions to help New Zealand’s health system better serve its people is at the heart of Medicines New Zealand’s message at the Trans Pacific Partnership meetings in Dallas this week. In a speech delivered to a stakeholder meeting in Dallas, Medicines New Zealand Chair Heather Roy has outlined the pharmaceutical industry’s support for the TPP. Medicines New Zealand believes improved access to innovative medicines will benefit New Zealand patients and a free trade agreement with eight other countries will give our economy a much needed boost. A recent economic projection of the expected benefits of the TPP estimates that by 2025 the TPP could add US$1.7 billion to New Zealand’s GDP[1]. “A good TPP will be good for New Zealand’s economy, it will be positive for our exporters and importers and it will help to bring this vibrant region closer together,” Mrs Roy says. “Contrary to popular misconception, the industry has no intention of using the TPP process to get rid of PHARMAC. “New Zealanders could have access to better and newer...

Read More